MGCD265: Additional Phase I/II data
MethylGene reported additional data from the Phase I portion of the ongoing, open-label, dose-escalation Phase I/II 265-103 trial evaluating oral MGCD256 in combination with either erlotinib or docetaxel. In 8 evaluable NSCLC patients, MGCD265 plus docetaxel produced 2 partial responses and 3 cases of prolonged disease stabilization. The MTD was twice-daily 72 mg/m 2 MGCD265 plus 75 mg/m 2 docetaxel. In patients receiving MGCD265 plus erlotinib, 1 patient with NSCLC achieved a partial response and 1 patient with gastric cancer experienced complete resolution of ascites and a decrease in gastric wall thickening. The MTD has not yet been reached for the MGCD256 plus erlotinib arm. The docetaxel and erlotinib arms have enrolled 24 and 34 patients, respectively. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...